---
title: "Stocks in Play: Satellos Bioscience Inc."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300050214.md"
description: "11:06 AM EST - Satellos Bioscience Inc. : Announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026. Satellos Bioscience Inc. shares T.MSCL are trading down $0.04 at $12.13."
datetime: "2026-09-24T15:10:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300050214.md)
  - [en](https://longbridge.com/en/news/300050214.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300050214.md)
generator: "portal-rs"
---

# Stocks in Play: Satellos Bioscience Inc.

**11:06 AM EST - Satellos Bioscience Inc. :** Announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026. Satellos Bioscience Inc. shares T.MSCL are trading **down $0.04** at $12.13.

### Related Stocks

- [MSLE.US](https://longbridge.com/en/quote/MSLE.US.md)

## Related News & Research

- [Satellos Bioscience Participates in Guggenheim, Jefferies Healthcare Conferences](https://longbridge.com/en/news/302552043.md)
- [Satellos Bioscience releases investor presentation on Duchenne muscular dystrophy program](https://longbridge.com/en/news/298645579.md)
- [9,713 Shares in SK hynix Inc. $SKHY Purchased by SeaCrest Wealth Management LLC](https://longbridge.com/en/news/302857522.md)
- [GRAPHIC-Take Five: AI trade meets the Fed](https://longbridge.com/en/news/302836715.md)
- [Western Digital Q1 Revenue Surges 55% YoY, Shares Drop Nearly 7%: Can $330 Support Hold?](https://longbridge.com/en/news/302840204.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**